Eris Lifesciences Q1 Profit Dips 4.5% to Rs 89 Cr
By Rediff Money Desk, New Delhi Aug 02, 2024 17:38
Eris Lifesciences reports a 4.5% decline in consolidated profit after tax to Rs 89 crore for Q1 FY25, while revenue rose to Rs 720 crore. The company expects significant growth in its Biocon business.
New Delhi, Aug 2 (PTI) Eris Lifesciences on Friday said its consolidated profit after tax declined by 4.5 per cent year on year to Rs 89 crore for the quarter ended on June 30, 2024.
The drug maker had reported a profit after tax of Rs 94 crore in the April-June quarter of the last fiscal.
Revenue rose to Rs 720 crore for the first quarter of 2024-25 from Rs 467 crore in the year-ago period, Eris Lifesciences said in a statement.
We have integrated the Biocon acquisitions well ahead of schedule and started realising significant synergies in our flagship domestic branded formulations business, which accounts for 90 per cent of our revenue," Eris Lifesciences Chairman & MD Amit Bakshi said.
The company expects to clock a growth of over 25 per cent in the Biocon business in FY25 with significant margin expansion, he added.
Eris has acquired commercial rights of Biocon Biologics' India-branded formulation business for Rs 1,242 crore. The drug firm said its board has approved execution of a binding term sheet to acquire a 100 per cent stake in Chemman Labs.
Shares of Eris Lifesciences on Friday ended 0.44 per cent up at Rs 1,124 apiece on the BSE.
The drug maker had reported a profit after tax of Rs 94 crore in the April-June quarter of the last fiscal.
Revenue rose to Rs 720 crore for the first quarter of 2024-25 from Rs 467 crore in the year-ago period, Eris Lifesciences said in a statement.
We have integrated the Biocon acquisitions well ahead of schedule and started realising significant synergies in our flagship domestic branded formulations business, which accounts for 90 per cent of our revenue," Eris Lifesciences Chairman & MD Amit Bakshi said.
The company expects to clock a growth of over 25 per cent in the Biocon business in FY25 with significant margin expansion, he added.
Eris has acquired commercial rights of Biocon Biologics' India-branded formulation business for Rs 1,242 crore. The drug firm said its board has approved execution of a binding term sheet to acquire a 100 per cent stake in Chemman Labs.
Shares of Eris Lifesciences on Friday ended 0.44 per cent up at Rs 1,124 apiece on the BSE.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- GTL Infrastructure
- 2.89 (+ 4.71)
- 121757816
- G V Films
- 0.91 (+ 2.25)
- 76902965
- Srestha Finvest
- 2.26 (+ 4.63)
- 55617757
- Vodafone Idea L
- 16.11 (+ 0.75)
- 46855004
- Suzlon Energy Ltd.
- 71.44 (+ 4.98)
- 30765378
MORE NEWS
![Delhivery Q1 FY25...](https://im.rediff.com/80-80/money/2024/jan/02jan-delhivery.jpg)
Delhivery Q1 FY25 Profit: Rs 54 cr, Revenue at...
Delhivery reported a profit after tax (PAT) of Rs 54 crore for the June quarter FY25, a...
![Indian Stock...](https://im.rediff.com/80-80/money/2021/jan/19wealth.jpg)
Indian Stock Market Plunges Rs 4.4 Lakh Crore:...
Indian equity investors lost Rs 4.46 lakh crore on Friday as the Sensex slumped 1.08%...
Meghalaya & Mother Dairy Partner for Agri...
Meghalaya govt signs MoU with Mother Dairy for agricultural marketing & supply chain...